Literature DB >> 20082977

Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease.

Elodie Angot1, Patrik Brundin.   

Abstract

Alpha-synuclein (alpha-syn) aggregation is central to neuropathological changes in Parkinson's disease. The aggregates spread within the central nervous system according to a very predictable pattern. A prion-like transmission of alpha-syn aggregates has been recently proposed to explain this propagation pattern. First, we review the growing evidence for such a mechanism. This process is likely to occur in three consecutive steps: (i) exit of alpha-syn template from the donor cell, (ii) entry to the recipient cell and (iii) initiation of the nucleation. In a second part, we discuss the possible underlying mechanisms for each of these steps, based on our current knowledge about how cells handle alpha-syn but also other proteins involved in neurodegenerative diseases with a prion-like propagation. Finally, we discuss which molecular species of alpha-syn (monomer, oligomer, fibril) could be the seeding-competent species and whether this seeding process could be a common mechanism in neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20082977     DOI: 10.1016/S1353-8020(09)70802-8

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  32 in total

Review 1.  Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease.

Authors:  Dawn Béraud; Kathleen A Maguire-Zeiss
Journal:  Parkinsonism Relat Disord       Date:  2012-01       Impact factor: 4.891

2.  α-Synuclein in gut endocrine cells and its implications for Parkinson's disease.

Authors:  Rashmi Chandra; Annie Hiniker; Yien-Ming Kuo; Robert L Nussbaum; Rodger A Liddle
Journal:  JCI Insight       Date:  2017-06-15

Review 3.  A deadly spread: cellular mechanisms of α-synuclein transfer.

Authors:  J A Steiner; E Angot; P Brundin
Journal:  Cell Death Differ       Date:  2011-05-13       Impact factor: 15.828

4.  Autophagy Modulation in Disease Therapy: Where Do We Stand?

Authors:  Michael P Nelson; John J Shacka
Journal:  Curr Pathobiol Rep       Date:  2013-12-01

5.  Nerve cells immunoreactive for p62 in select hypothalamic and brainstem nuclei of controls and Parkinson's disease cases.

Authors:  Heiko Braak; Dietmar R Thal; Kelly Del Tredici
Journal:  J Neural Transm (Vienna)       Date:  2010-11-05       Impact factor: 3.575

Review 6.  Parkinson's disease from the gut.

Authors:  Rodger A Liddle
Journal:  Brain Res       Date:  2018-01-31       Impact factor: 3.252

Review 7.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

8.  Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-14       Impact factor: 17.088

Review 9.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

10.  Connectivity Analysis is Essential to Understand Neurological Disorders.

Authors:  James B Rowe
Journal:  Front Syst Neurosci       Date:  2010-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.